By: IPP Bureau
Last updated : August 31, 2026 6:39 am
FDA classifies July inspection of InvaGen Pharmaceuticals’ Unit 3 facility as Voluntary Action Indicated following review of manufacturing operations
Cipla Limited has informed stock exchanges that the US Food and Drug Administration (USFDA) has classified its recent inspection of InvaGen Pharmaceuticals Inc.’s Unit 3 manufacturing facility in New York as “Voluntary Action Indicated” (VAI).
InvaGen Pharmaceuticals is a wholly owned subsidiary of Cipla. The USFDA inspection at the facility, located in Central Islip, Long Island, New York, was conducted from July 13 to July 17, 2026.
According to Cipla’s regulatory filing, the company received communication from the USFDA regarding the VAI classification on August 28, 2026. Cipla had earlier informed the exchanges about the inspection on July 18.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and was submitted to BSE Limited, the National Stock Exchange of India and the Société de la Bourse de Luxembourg.
A Voluntary Action Indicated (VAI) classification generally means that the USFDA has identified certain regulatory observations or deficiencies during an inspection that require corrective action, but the agency has determined that formal enforcement action is not currently indicated.
Under a VAI classification, the company is generally expected to address the observations voluntarily and implement appropriate corrective and preventive measures. The classification does not, by itself, mean that the facility has been placed under an FDA enforcement action.
For Cipla’s InvaGen facility, the VAI classification follows the completion of the July inspection and the FDA’s subsequent regulatory assessment.
The classification is distinct from an Official Action Indicated (OAI) designation, under which the FDA determines that regulatory action is warranted.
Cipla’s latest disclosure follows a series of regulatory inspections across pharmaceutical manufacturing facilities as US and Indian regulators continue to scrutinise compliance with current good manufacturing practices and other quality requirements.